Literature DB >> 6352629

Pharmacokinetics of ceftazidime in patients undergoing peritoneal dialysis.

A Tourkantonis, P Nicolaidis.   

Abstract

The pharmacokinetics of ceftazidime were studied in 12 patients during peritoneal dialysis. In five patients given 1 g iv the mean serum levels (mg/l) at 0.25, 2 and 12 h after starting peritoneal dialysis were 50.6 +/- 11.2, 35.6 +/- 3.7 and 22.7 +/- 7.9, respectively. The mean ceftazidime peak level was 13.2 +/- 5.5 mg/l in peritoneal effluent, approximately 3 h after start of dialysis. The peritoneal clearance was 9 ml/min and the mean half-life during and after peritoneal dialysis was 8.7 +/- 3.1 h and 26.9 +/- 11 h, respectively. In four patients, 1 g ceftazidime was given via an intraperitoneal catheter. The mean serum levels (mg/l) at 0.25, 2 and 8 h were 14.2 +/- 3.1, 40.0 +/- 13.0 and 32.5 +/- 6.4 respectively. In three patients given ceftazidime 200 mg, in 21 dialysate treatments each with 12 cycles, mean serum levels increased from 1.3 +/- 1.5 mg/l at 1 h to 25.3 +/- 3.1 mg/l at 12 h. Mean levels in the dialysis effluent were 47.2 +/- 14.3 mg/l and the mean percentage of the dose recovered in the effluent was 47.1%. We concluded that (1) 1 g ceftazidime as an iv bolus maintained serum and peritoneal effluent levels adequate to treat patients; (2) its peritoneal absorption produced high ceftazidime levels in serum; (3) in infected patients undergoing peritoneal dialysis ceftazidime may be given either by the intravenous or intraperitoneal route.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6352629     DOI: 10.1093/jac/12.suppl_a.263

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  5 in total

1.  Pharmacokinetics of cefepime in patients undergoing continuous ambulatory peritoneal dialysis.

Authors:  R H Barbhaiya; C A Knupp; M Pfeffer; D Zaccardelli; G M Dukes; W Mattern; K A Pittman; L J Hak
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

2.  Reevaluation of ceftazidime dosing recommendations in patients on continuous ambulatory peritoneal dialysis.

Authors:  Katie E Cardone; Darren W Grabe; Evan J Zasowski; Thomas P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2013-10-14       Impact factor: 5.191

Review 3.  Drug therapy in patients undergoing peritoneal dialysis. Clinical pharmacokinetic considerations.

Authors:  T W Paton; W R Cornish; M A Manuel; B G Hardy
Journal:  Clin Pharmacokinet       Date:  1985 Sep-Oct       Impact factor: 6.447

Review 4.  Cefepime clinical pharmacokinetics.

Authors:  M P Okamoto; R K Nakahiro; A Chin; A Bedikian
Journal:  Clin Pharmacokinet       Date:  1993-08       Impact factor: 6.447

Review 5.  Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Richards; R N Brogden
Journal:  Drugs       Date:  1985-02       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.